Background:The efficacy of treatment with nucleos(t)ide analogues (NAs) in non-cirrhotic chronic hepatitis B (CHB) patients is well-established. However, its impact on complications of portal hypertension in advanced chronic liver disease (ACLD) is less well-characterized.Methods: MEDLINE/PubMed, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, and abstracts of major international hepatology meetings were searched for publications from Jan 1, 1995 to Nov 30, 2021. Randomized control trials and observational studies reporting the efficacy of NAs in ACLD patients were eligible. Pooled risk ratios (RRs) for outcomes of interest were calculated with a random-effect or fixed-effect model, as propriate.Results: Thirty-nine studies including 14 212 ACLD patients were included. NA treatment was associated with reduced risks of overall hepatic decompensation events (RR, 0.51; 95% confidence interval [CI]: 0.37-0.71) such as variceal bleeding (RR, 0.44; 95% CI: 0.26-0.74) and also ascites (RR, 0.10; 95% CI: 0.01-1.59) on a trend-wise level. Moreover, the risks of hepatocellular carcinoma (HCC) (RR, 0.48; 95% CI: 0.30-0.75) and liver transplantation/death (RR, 0.36; 95% CI: 0.25-0.53) were also reduced by NA treatment and first-line NAs were superior to non-first-line NAs in regard to these outcomes (RR, 0.85; 95% CI: 0.75-0.97 and RR, 0.85; 95% CI: 0.73-0.99, respectively).
Conclusion:NA therapy lowers the risk of portal hypertension-related complications including variceal bleeding, as well as HCC, and liver transplantation/death.
